Skip to main content

Table 4 Characteristics and recent treatments/conditions of patients with anti-IL-1therapy discontinuation for various reasons

From: Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever

 

Age

Sex

Mutation

Dominant clinical features and the Reasons for Discontinuation of Anti-IL1 Treatment

Duration of Using Anti-IL-1 agents

Recent treatments/conditions

Patient 1

21

F

M694 V homozygous

Amyloidosis Stage 5 CRD 11 g/day proteinuria

İncrease of proteinuria, Progression of CRD

Anakinra/12 months

Renal tx

Patient 2

28

M

M694 V heterozygous

M680I heterozygous

PAN+sacroiliitis

Activation of PAN/high dose corticosteroid

Anakinra/12 months

Sepsis-died

Patient 3

25

M

M694 V heterozygous

M680I heterozygous

Sacroiliitis

refractory low back pain

high BASDAI score

Canakinumab/4 months

Anti-TNF

Patient 4

24

M

M694 V homozygous

Sacroiliitis

refractory low back pain

high BASDAI score

Canakinumab/6 months

Anti-TNF

Patient 5

50

M

R761H homozygous

Sacroiliitis+polyarthritis

Refractory arthritis

Canakinumab/18 months (secondary non-responder)

Tocilizumab

Patient 6

19

M

M680I homozygous

Peripheral Arthritis

Refractory arthritis

Anakinra/3 months

Tocilizumab

Patient 7

49

M

M694 V homozygous

Amyloidosis

Stage 4 CRD

2.5 g/day proteinuria

İncrease of proteinuria

Canakinumab/4 months

Tocilizumab

Patient 8

45

F

M694 V heterozygous

 

Side effect

Anakinra/2 years

Multiple sclerosis-drug stop

  1. PAN polyarteritis nodosa, CRD Chronic Renal Disease, Renal tx renal transplant, (BASDAI) Bath Ankylosing Spondylitis Disease Activity Index, TNF Tumour necrosis factor, IL interleukin